Answers are grounded in this paper and cite their sources.
The increasing prevalence of Plasmodium falciparum parasites carrying Pf hrp2/3 deletions threatens the reliability of PfHRP2-based rapid diagnostic tests (RDTs), particularly in the malaria-endemic regions. This study clinically evaluated native PfEXP1 (nPfEXP1) as a candidate diagnostic biomarker and investigated its global genetic diversity. Polyclonal and monoclonal anti-PfEXP1 antibodies detected nPfEXP1 in cultured parasites at estimated amounts of 0·14 and 0·014 ng, respectively. Monoclonal antibodies also detected nPfEXP1 in cultured parasites carrying Pf hrp2 or Pf hrp2/3 deletions. In a cross-sectional Phase II biomarker evaluation involving 121 P. falciparum -positive samples and 80 malaria-negative controls from India, indirect ELISA demonstrated significantly higher nPfEXP1 reactivity in the parasite density-segregated infected samples than in the controls (p < 0·0001). The cohort was randomly divided into training and validation subsets in a 70:30 ratio. At the training-derived cutoff, the PfEXP1 index assay achieved 86% sensitivity (95% CI, 71–95) and 58% specificity (95% CI, 37–78) in the validation subset, compared with 95% sensitivity (95% CI, 82–99) and 88% specificity (95% CI, 69–96) for the PfHRP2 comparator assay. Analysis of the MalariaGEN Pf8 dataset revealed geographically clustered PfEXP1 polymorphisms, including recurrent variations at amino acid positions 136 and 160, while the examined epitope region remained largely conserved. These findings support PfEXP1 as a potential complementary diagnostic antigen and provide a basis for developing monoclonal antibody-based sandwich assays and evaluating their performance in larger, geographically diverse clinical cohorts.
No takes yet. Share an insight, caveat, or question.
Pandey et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: